Efficacy and Safety of Autologous Cultivated Limbal Stem Cells Transplantation (ACLSCT) for Restoration of Corneal Epithelium in Patients With Limbal Stem Cell Deficiency (HOLOCORE)
Multinational, Multicentre, Prospective, Open-label, Uncontrolled Clinical Trial to Assess the Efficacy and Safety of Autologous Cultivated Limbal Stem Cells Transplantation (ACLSCT) for Restoration of Corneal Epithelium in Patients With Limbal Stem Cell Deficiency Due to Ocular Burns (HOLOCORE)
Sponsor: Holostem s.r.l.
This PHASE4 trial investigates Limbal Stem Cells Deficiency and is currently completed. Holostem s.r.l. leads this study, which shows 12 recorded versions since 2015 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
12 versions recorded-
Mar 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Mar 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
May 2022 — Jul 2024 [monthly]
Completed PHASE4
Status: Active Not Recruiting → Completed
-
Sep 2021 — May 2022 [monthly]
Active Not Recruiting PHASE4
▶ Show 7 earlier versions
-
Mar 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE4
-
Jan 2021 — Mar 2021 [monthly]
Active Not Recruiting PHASE4
-
Sep 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE4
Status: Recruiting → Active Not Recruiting
-
Jan 2020 — Sep 2020 [monthly]
Recruiting PHASE4
-
Dec 2018 — Jan 2020 [monthly]
Recruiting PHASE4
-
Jun 2018 — Dec 2018 [monthly]
Recruiting PHASE4
-
Jan 2017 — Jun 2018 [monthly]
Recruiting PHASE4
First recorded
Oct 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Holostem s.r.l.
For direct contact, visit the study record on ClinicalTrials.gov .